Clindamycin Hydrochloride Capsules Recalled for Manufacturing Practice Deviations
Preferred Pharmaceuticals, Inc. is recalling 1190 bottles of Clindamycin Hydrochloride Capsules nationwide due to manufacturing practice deviations. The product was manufactured by Glenmark Pharmaceuticals Limited.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a Class II voluntary recall for cGMP deviations with no reported illnesses or injuries. It fits the category of voluntary precautionary recalls initiated by the firm to address manufacturing practice compliance issues.
Plain-English summary
Preferred Pharmaceuticals, Inc. is recalling Clindamycin Hydrochloride Capsules, USP, 300mg (NDC 68788-8685-03) distributed nationwide in the United States. The affected lot numbers are L0224T, K1824M, K0124N, J1624V, J0824O, I2424E, I1024O, A0925F, and L2324L, with an expiration date of 7/31/2026. A total of 1190 bottles are affected.
The recall was initiated on April 18, 2025, due to cGMP (current good manufacturing practice) deviations. This is a voluntary recall initiated by the firm. The product was manufactured by Glenmark Pharmaceuticals Limited.
Patients or healthcare providers with this product should seek guidance from their healthcare provider regarding their treatment options.
The recalled product
- Product
- Clindamycin Hydrochloride Capsules, USP, 300mg, 30-count bottles, Manufactured by: Glenmark Pharmaceuticals Limited, NDC 68788-8685-03.
- Manufacturer
- Preferred Pharmaceuticals, Inc.
- Category
- Drug
- Hazard
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (10)
- Lot #: L0224T
- K1824M
- K0124N
- J1624V
- J0824O
- I2424E
- I1024O
- A0925F
- L2324L
- Exp: 7/31/2026.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27